BusinessThe EndoPredict® Test Receives Positive Coverage Decisions from Multiple Blue Cross Blue Shield Affiliate PlansBy Nasdaq OMXJan 6, 2017, 12:05 PM UTC
BusinessEndoPredict® Reviewed by Blue Cross Blue Shield Association’s Evidence StreetBy Nasdaq OMXJan 5, 2017, 12:05 PM UTC
BusinessChromaDex Opens New State-of-the-Art Research and Development Center in LongmontBy Nasdaq OMXJan 5, 2017, 11:30 AM UTC
BusinessPositive Clinical Utility Results of Crescendo’s Vectra® DA Test for Rheumatoid Arthritis Published in the Journal Arthritis & RheumatologyBy Nasdaq OMXDec 27, 2016, 12:05 PM UTC
BusinessUnited Rheumatology Issues Clinical Practice Guidelines and Recommends the Vectra® DA Test for Adults with Rheumatoid ArthritisBy Nasdaq OMXDec 22, 2016, 7:03 PM UTC
BusinessPositiveID Corporation Discusses 2016 Highlights in New Interview with SmallCapVoice.comBy Nasdaq OMXDec 19, 2016, 1:00 PM UTC
BusinessThe EndoPredict® Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-Positive Breast Cancer RecurrenceBy Nasdaq OMXDec 9, 2016, 12:05 PM UTC
BusinessThe Fight Against Prostate Cancer: What Men Need to KnowBy Nasdaq OMXDec 8, 2016, 2:00 PM UTC
